checkAd

Chart

Technische Analyse in EUR

52 Wochen
Tief
4,210
Hoch
9,850
200 Tage
Tief
5,350
Hoch
9,850
Heute
Tief
8,650
Hoch
8,725

Neuigkeiten

ZeitTitel
SmartbrokerSmartbroker: Ab 0€ pro Order handeln mit dem Testsieger (Finanztest 11/2020) Anzeige
29.04.21Avadel Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2021 Financial Results on May 10th
globenewswire | Weitere Nachrichten
17.04.21Avadel Presents New Data from its Pivotal REST-ON Phase 3 Trial of FT218, once-nightly sodium oxybate, at the 2021 American Academy of Neurology Annual Meeting
globenewswire | Weitere Nachrichten
08.04.21Avadel to Present New Data from its Pivotal REST-ON Phase 3 Study of FT218 at the American Academy of Neurology Annual Meeting 2021
globenewswire | Weitere Nachrichten
18.03.21Avadel Pharmaceuticals to Participate in a Fireside Chat at Stifel’s Third Annual CNS Day on March 31st
globenewswire | Weitere Nachrichten
09.03.21Avadel Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 Financial Results
globenewswire | Weitere Nachrichten
04.03.21Avadel Pharmaceuticals and the American Academy of Sleep Medicine Foundation Announce an Exclusive Collaboration on the 2021 Young Investigators Research Forum
globenewswire | Weitere Nachrichten
02.03.21Avadel Pharmaceuticals Announces Publication of Once-Nightly FT218 Pharmacokinetic Studies
globenewswire | Weitere Nachrichten
01.03.21Avadel Pharmaceuticals Announces FDA Acceptance of New Drug Application for FT218 in Adults with Narcolepsy for the Treatment of Excessive Daytime Sleepiness and Cataplexy
globenewswire | Weitere Nachrichten
25.02.21Avadel Pharmaceuticals to Participate in Fireside Chats at Upcoming March 2021 Investor Conferences
globenewswire | Weitere Nachrichten
24.02.21Avadel Pharmaceuticals to Provide a Company Update and Report Fourth Quarter and Full Year 2020 Financial Results, on March 9th
globenewswire | Weitere Nachrichten
17.02.21Avadel Pharmaceuticals Appoints Richard Kim as Chief Commercial Officer to Lead the Commercial Launch of Once-Nightly FT218
globenewswire | Weitere Nachrichten
10.02.21Avadel Pharmaceuticals to Participate in a Fireside Chat at the 10th Annual SVB Leerink Global Healthcare Conference
globenewswire | Weitere Nachrichten
16.12.20Avadel Pharmaceuticals Announces Submission of New Drug Application for FT218 to the FDA
globenewswire | Weitere Nachrichten
15.12.20Avadel Pharmaceuticals Added to NASDAQ Biotechnology Index
globenewswire | Weitere Nachrichten
Insidertrade: :

Aktienkurs

BörsenplatzLang & Schwarz
Letzter Kurs8,725EUR
Performance0,00 %
Kurszeit12:39:22
Eröffnung8,725EUR
Tageshoch8,725EUR
Tagestief8,650EUR
Vortageskurs8,725EUR
Volumen1,10 Tsd.Stk.
52-Wochen Hoch9,850EUR
52-Wochen Tief4,210EUR
Anzahl Trades3
Performance 1 Monat+31,70 %
Performance 1 Jahr+88,04 %

Performance

ZeitKursPerf.
1 Tag8,725EUR
0,00 %
1 Woche8,625EUR
+1,16 %
1 Monat6,625EUR
+31,70 %
3 Monate5,700EUR
+53,07 %
6 Monate7,300EUR
+19,52 %
Lfd. Jahr5,125EUR
+70,24 %
1 Jahr4,640EUR
+88,04 %

Stammdaten

NameAvadel Pharmaceuticals PLC
KurznameAvadel Pharma
NamenszusatzShs Sponsored American Depositary Receipt Repr 1 Sh
KategorieAktien
AktientypStammaktien
WKNA2DJR8
BranchePharmaindustrie
LandIrland Irland
ReferenzwährungEUR
Aktienanzahl58,60 Mio.
Marktkapitalisierung511,25 Mio.EUR

Kontaktdaten

NameAvadel Pharmaceuticals PLC
StadtDublin
LandIrland Irland

Aktionäre interessieren sich auch für:

#WertpapierPerf. %
1.+0,34
2.-6,53
3.-2,86
4.-1,82
5.-1,78
6.+1,29
7.+0,20
8.-0,43
9.+0,47
10.-1,07